IP Library Granted Patent US 8,865,216
Granted Patent B2
US 8,865,216 · App. 12/184,715 · Granted Oct 21, 2014

Surface-modified nanoparticles for intracellular delivery of therapeutic agents and composition for making same

Inventors: Vinod Labhasetwar (Solon, OH); Jaspreet Vasir (Cleveland, OH)
Assignees: National Institutes of Health (NIH); U.S. Dept. of Health and Human Services (DHHS)
A61K9/5153A61K9/5146Y10S977/773Y10S977/906
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,865,216
App. No.
12/184,715
Granted
Oct 21, 2014
Kind
B2
Abstract

Surface-modified polymeric nanoparticles (NPs), compositions for making them, and their use in drug delivery are disclosed.

Claims (5)

1. A surface modified nanoparticle for delivery of therapeutic agents, said surface modified nanoparticle comprising (i) a biocompatible polymer (ii) an amphiphilic emulsifier and (iii) a charge modulator, wherein said biocompatible polymer is poly(lactide-co-glycolide), said amphiphilic emulsifier is polyvinyl alcohol and said charge modulator is poly-L-lysine, (i), (ii) and (iii) forming a nanoparticle matrix, the weight ratio of said amphiphilic emulsifier to said charge modulator from which said nanoparticle is prepared is in the range of 4:1 to 1.5:1, said nanoparticle having a negative surface charge at neutral pH, said charge modulator being embedded in said nanoparticle matrix and extending from the nanoparticle surface, and said charge modulator being effective to reverse said surface charge from negative to positive in an acidic environment, thereby improving the efficiency of intracellular delivery of therapeutic agents carried by said nanoparticle, said surface modified nanoparticle having a greater force of adhesion to a cell membrane for enhancing cellular uptake of said nanoparticle as compared to an unmodified nanoparticle comprising said biocompatible polymer and said amphiphilic emulsifier without said charge modulator.

2. The modified nanoparticle of claim 1 , further including a therapeutic agent.

3. A pharmaceutical preparation comprising a multiplicity of the nanoparticles of claim 2 .

4. The modified nanoparticle of claim 1 , further including a diagnostic agent.

5. A method for delivery of a therapeutic or diagnostic agent to a patient, said method comprising administering to said patient a multiplicity of nanoparticles as claimed in claim 1 also including an effective amount of said therapeutic or diagnostic agent.

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded Jun 15, 2026
From: VCT INVESTMENTS, INC.
To: ADVANCED NANOTHERAPIES INC.
Reel/Frame 075761/0067 →
SECURITY INTEREST Recorded Feb 3, 2026
From: ADVANCED NANOTHERAPIES INC.
To: VCT INVESTMENTS, INC.
Reel/Frame 073670/0741 →
CONFIRMATORY LICENSE Recorded Apr 30, 2010
From: UNIVERSITY OF NEBRASKA MEDICAL CENTER
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 024315/0122 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 4, 2009
From: LABHASETWAR, VINOD; VASIR, JASPREET K.
To: BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA
Reel/Frame 022208/0235 →
Continuity (2)
Provisional Application 60953912 · Aug 3, 2007
Related Publication 20090136585A1 · May 28, 2009